Emerging Infectious Disease ISSN: 1080-6059
Volume 17, Number 6—June 2011
CME ACTIVITY
Cefepime-Resistant Pseudomonas aeruginosa
Earning Medscape CME Credit
To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions and earn continuing medical education (CME) credit, please go to www.medscape.org/journal/eid. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers. You must be a registered user on Medscape.org. If you are not registered on Medscape.org, please click on the New Users: Free Registration link on the left hand side of the website to register. Only one answer is correct for each question. Once you successfully answer all post-test questions you will be able to view and/or print your certificate. For questions regarding the content of this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@webmd.net. American Medical Association's Physician's Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please refer to http://www.ama-assn.org/ama/pub/category/2922.html. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit is acceptable as evidence of participation in CME activities. If you are not licensed in the US and want to obtain an AMA PRA CME credit, please complete the questions online, print the certificate and present it to your national medical association.
Cefepime-Resistant Pseudomonas aeruginosa
Medscape CME Questions
1. You are seeing a 61-year-old man admitted for pneumonia. His blood culture is now growing Pseudomonas aeruginosa, and you are concerned regarding the possibility of antimicrobial resistance of this organism.
What was the approximate rate of resistance to cefepime among isolates of P. aeruginosa in the current study?
A. Less than 1%
B. 8%
C. 22%
D. 47%
2. Which of the following variables independently increased the risk for P. aeruginosa resistance to cefepime in the current study?
A. Male sex
B. Diagnosis of pneumonia
C. Higher Charlson index score
D. Transfer from another facility
3. The patient was treated with antibiotics as an outpatient prior to hospital admission. Prior treatment with which classes of antibiotics was found to increase the risk for cefepime-resistant P. aeruginosa (CRPA) in the current study?
A. Aminoglycosides only
B. Extended-spectrum cephalosporins only
C. Extended-spectrum cephalosporins, extended-spectrum penicillins, and quinolones
D. Aminoglycosides, extended-spectrum penicillins, and macrolides
4. The patient is diagnosed with CRPA. What does the current study suggest regarding the effect of CRPA vs. cefepime-sensitive P. aeruginosa on the risk for mortality?
A. CRPA did not confer a higher risk for mortality in any analysis
B. Only older patients with CRPA were at a higher risk for death
C. Only patients with blood isolates for CRPA were at a higher risk for death
D. Any infection with CRPA was associated with a higher risk for death
Activity Evaluation
| 1. The activity supported the learning objectives. | ||||
| Strongly Disagree |
Strongly Agree
|
|||
|
1
|
2
|
3
|
4
|
5
|
| 2. The material was organized clearly for learning to occur. | ||||
| Strongly Disagree |
Strongly Agree
|
|||
|
1
|
2
|
3
|
4
|
5
|
| 3. The content learned from this activity will impact my practice. | ||||
| Strongly Disagree |
Strongly Agree
|
|||
|
1
|
2
|
3
|
4
|
5
|
| 4. The activity was presented objectively and free of commercial bias. | ||||
| Strongly Disagree |
Strongly Agree
|
|||
|
1
|
2
|
3
|
4
|
5
|
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
New Flu Virus in Pigs Exhibited at Fairs in Ohio
Length: 11:58





